Embera NeuroTherapeutics, Inc.

16 articles about Embera NeuroTherapeutics, Inc.

• Embera NeuroTherapeutics Announces First Subject Dosed in Phase 2a Study of EMB-001 in Smoking Cessation

  6/30/2021

  Embera NeuroTherapeutics Announces First Subject Dosed in Phase 2a Study of EMB-001 in Smoking Cessation

• Embera NeuroTherapeutics Announces First Subject Dosed in Phase 2 Study of EMB-001 in Cocaine Use Disorder

  8/31/2020

  Embera NeuroTherapeutics, Inc., a specialty pharmaceutical company developing novel treatments for cocaine, nicotine and potentially other addictions, today announced that the first subjects have begun dosing of EMB-001 in a Phase 2 study for cocaine use disorder.

• Embera NeuroTherapeutics Completes Series B Financing and Receives Grants to Advance EMB-001 into Phase 2 Clinical Studies in Cocaine Use Disorder and Smoking Cessation

  12/19/2019

  Embera appoints Bruce McCarthy, M.D. as Chief Medical Officer Gary Connor, RN promoted to Chief Operating Officer

• Embera NeuroTherapeutics, Inc. Announces Positive Topline Data From Phase Ib Cocaine Interaction Study Of EMB-001

  5/8/2017

• Embera NeuroTherapeutics, Inc. Receives $11M Grant From National Institute on Drug Abuse (NIDA) For The Clinical Development Of EMB-001 For The Treatment Of Cocaine Addiction

  7/26/2016

• Embera NeuroTherapeutics, Inc. Announces Successful Completion Of Phase 1 Clinical Trial Testing EMB-001, A Potential Novel Treatment For Addictions

  1/6/2016

• Embera NeuroTherapeutics, Inc. Initiates Phase 1 Clinical Trial To Test EMB-001 As A Novel Treatment For Addictions

  5/28/2015

• Embera NeuroTherapeutics, Inc. Secures A-2 Financing To Advance EMB-001 For Addictions Through Phase 1 Clinical Trial

  4/10/2015

• Embera NeuroTherapeutics, Inc. To Receive Grant For Clinical Trial Through New Crowd Funding Platform

  7/1/2014

• Embera NeuroTherapeutics, Inc. and Collaborators Publish Paper in Psychopharmacology Supporting its Novel Drug Combination, EMB-001, for Smoking Cessation

  3/19/2012

• Embera NeuroTherapeutics, Inc. Takes In $4.5 Million Series A Financing

  8/15/2011

• Embera NeuroTherapeutics, Inc.’ Lead Candidate, EMB-001, Supported by $3.9M Grant from National Institute on Drug Abuse

  10/1/2010

• Embera NeuroTherapeutics, Inc.' Lead Candidate, EMB-001, Supported by $3.9M Grant from National Institute on Drug Abuse (NIDA)

  10/1/2010

• Embera NeuroTherapeutics, Inc. Forms Clinical Development Collaboration with Exponential Pharma Ventures

  2/16/2010

• Embera NeuroTherapeutics, Inc. Announces Expansion of Management Team after Successful Completion of Pilot Study of Cocaine Addiction Treatment

  7/20/2009

• Embera NeuroTherapeutics, Inc. Scientific Advisory Board is Formed with Distinguished Professors Renowned in Addiction Research

  5/18/2007